A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study

被引：0
|
作者：
Daniele, Bruno
Di Maio, Massimo
Gallo, Ciro
Gasbarrini, Antonio
Carteni, Giacomo
Di Costanzo, Giovan Giuseppe
Craxi, Antonio
Cabibbo, Giuseppe
Bolondi, Luigi
Granito, Alessandro
Missale, Gabriele
Frassoldati, Antonio
Angelico, Mario
Roselli, Mario
Daniele, Gennaro
Perrone, Francesco
机构：
[1] G Rummo Hosp, Benevento, Italy
[2] Natl Canc Inst, Clin Trials Unit, Naples, Italy
[3] Univ Naples 2, Naples, Italy
[4] Policlin Univ Agostino Gemelli, Rome, Italy
[5] Azienda Osped Rilievo Nazl A Cardarelli, Naples, Italy
[6] Azienda Osped Univ, Policlin Paolo Giaccone, Palermo, Italy
[7] Azienda Osped Univ Policlin St Orsola Malpighi, Bologna, Italy
[8] Azienda Osped Univ Parma, Parma, Italy
[9] Az Osped Univ Arcispedale St Anna Ferrara, Ferrara, Italy
[10] Azienda Osped Univ Policlin Tor Vergata, Rome, Italy
[11] Natl Canc Inst, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4151
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
    Kang, Jung Hun
    Lee, Soon Il
    Lim, Do Hyoung
    Park, Keon-Woo
    Oh, Sung Yong
    Kwon, Hyuk-Chan
    Hwang, In Gyu
    Lee, Sang-Cheol
    Nam, Eunmi
    Shin, Dong Bok
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Se Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (13) : 1513 - 1518
  • [42] Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
    Qin, Shukui
    Fang, Weijia
    Ren, ZhengGang
    Shuangyan, Ou
    Lim, Ho Yeong
    Zhang, Feng
    Choi, Hye Jin
    Tong, Jiandong
    Tao, Min
    Xu, Aibing
    Cheng, Ashley Chi Kin
    Lu, Chang-Hsien
    Chiu, Chang-Fang
    Wahid, Mohamed Ibrahim A.
    Kamble, Shital
    Norquist, Josephine M.
    Zhong, Wen Yan
    Li, Chen
    Chen, Zhendong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han-Chong
    Gorbunova, Vera
    Eskens, Ferry A. L. M.
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El-Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
  • [44] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.
    Ikeda, Masafumi
    Shimizu, Satoshi
    Sato, Tosiya
    Morimoto, Manabu
    Inaba, Yoshitaka
    Kojima, Yasushi
    Hagihara, Atsushi
    Kudo, Masatoshi
    Nakamori, Shoji
    Kaneko, Shuichi
    Sugimoto, Rie
    Tahara, Toshiyuki
    Ohmura, Takumi
    Yasui, Kohichiroh
    Sato, Keiko
    Ishii, Hiroshi
    Furuse, Junji
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)
    Kuboki, Y.
    Yoshino, T.
    Yamazaki, K.
    Nishina, T.
    Komatsu, Y.
    Baba, H.
    Tsuji, A.
    Yamaguchi, K.
    Muro, K.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S392 - S392
  • [47] The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17
    Vickers, M. M.
    Karapetis, C. S.
    Tu, D.
    O'Callaghan, C. J.
    Price, T. J.
    Tebbutt, N. C.
    Van Hazel, G.
    Shapiro, J. D.
    Pavlakis, N.
    Gibbs, P.
    Blondal, J.
    Lee, U. J. Yu Min
    Meharchand, J. M.
    Burkes, R. L.
    Rubin, S. H.
    Simes, J.
    Zalcberg, J. R.
    Moore, M. J.
    Zhu, L.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kudo, Masatoshi
    Bouattour, Mohamed
    Lim, Ho-Yeong
    Breder, Valeriy Vladimirovich
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Ebbinghaus, Scot
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345